APA (7th ed.) Citation

KS, T., X, Y., S, N., M, P., K, Y., MF, P., . . . M, Z. (2022). Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. Clinical pharmacology and therapeutics, 112(3), 573. https://doi.org/10.1002/cpt.2670

Chicago Style (17th ed.) Citation

KS, Taskar, et al. "Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective." Clinical Pharmacology and Therapeutics 112, no. 3 (2022): 573. https://doi.org/10.1002/cpt.2670.

MLA (9th ed.) Citation

KS, Taskar, et al. "Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective." Clinical Pharmacology and Therapeutics, vol. 112, no. 3, 2022, p. 573, https://doi.org/10.1002/cpt.2670.